Cormorant Asset Management’s Enliven Therapeutics ELVN Stock Holding History

Cormorant Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.61M	Buy	+150,000	New	+$6.37M	0.39%	36
2025 Q4	–	Sell	-200,000	Closed	-$4.09M	–	39
2025 Q3	$4.09M	Hold	200,000	–	–	0.28%	35
2025 Q2	$4.01M	Sell	200,000 -50,000	-20%	-$947K	0.3%	38
2025 Q1	$4.92M	Hold	250,000	–	–	0.37%	39
2024 Q4	$5.63M	Buy	+250,000	New	+$6.48M	0.31%	36
2023 Q4	–	Sell	-1,216,712	Closed	-$16.6M	–	51
2023 Q3	$16.6M	Sell	1,216,712 -719,421	-37%	-$12.1M	0.97%	26
2023 Q2	$39.5M	Hold	1,936,133	–	–	2.21%	10
2023 Q1	$42.4M	Buy	+1,936,133	New	+$39.4M	2.79%	9

Other funds holding ELVN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Cormorant Asset Management's ELVN Position: Q2 2026 in Review

Cormorant Asset Management opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 150,000 shares worth $7.61M. The stake represents 0.39% of the portfolio and ranks #36 among its holdings. This is a return to the name: Cormorant Asset Management previously reported a position in ELVN as recently as Q3 2025.

Cormorant Asset Management first reported a position in ELVN in Q1 2023 and has held it in 8 quarters since. The position peaked at $42.4M in Q1 2023. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

Cormorant Asset Management held 150,000 shares of Enliven Therapeutics worth $7.61M as of Q2 2026.
Enliven Therapeutics was a new Cormorant Asset Management position in Q2 2026.
Enliven Therapeutics made up 0.39% of Cormorant Asset Management's portfolio in Q2 2026, its #36 holding.
Cormorant Asset Management first reported a position in Enliven Therapeutics in Q1 2023 and has held it in 8 quarters since.
Cormorant Asset Management's Enliven Therapeutics position peaked at $42.4M in Q1 2023.
213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.